Search clinical trials for: GES (Gemcitabine, Erlotinib, S-1)

Total 1214 results

Hallym University Medical Center
Jeil Pharmaceutical Co., Ltd.

Completed

S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

Pancreas Neoplasms

Korea, Republic of
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
Gyeongsang National University Hospital
Samsung Medical Center; Dong-A University; Chung-Ang University

Terminated

Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer

Metastatic Biliary Tract Cancer | Locally Advanced Biliary Tract Cancer

Korea, Republic of
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
Kansai Hepatobiliary Oncology Group

Completed

A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy

Biliary Tract Cancer

Japan
Kansai Hepatobiliary Oncology Group

Completed

GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer

Biliary Tract Cancer

Japan
Osaka Medical Center for Cancer and Cardiovascular...

Completed

Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer

Pancreatic Cancer

Japan
Kansai Hepatobiliary Oncology Group

Unknown

A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis

Biliary Tract Cancer

Japan
Kansai Hepatobiliary Oncology Group

Completed

Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer

Biliary Tract Cancer

Japan
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
Chang Gung Memorial Hospital

Recruiting

Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma (GAS)

Metastatic Pancreatic Adenocarcinoma

Taiwan
Tomoshi Tsuchiya

Completed

A Feasibility Study of Oral Adjuvant Chemotherapy With S-1

Non-small Cell Lung Cancer

Japan
AstraZeneca

Recruiting

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (TOURMALINE)

Biliary Tract Cancer

France, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
Fudan University
The First Affiliated Hospital of Anhui Medical University; Guangdong Provincial... and other collaborators

Withdrawn

Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.

Gastric Cancer

China
Spanish Cooperative Group for the Treatment of...
Hoffmann-La Roche

Completed

Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer (GECA)

Metastatic Pancreatic Cancer

Spain
Japan Clinical Cancer Research Organization

Completed

GEM vs GEM+TS-1 for Advanced Pancreatic Cancer

Pancreatic Cancer

Japan
Dana-Farber Cancer Institute

Withdrawn

OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

Pancreatic Cancer, Metastatic

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Breast Cancer

United States
Georgetown University

Unknown

Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease (AD)

Alzheimer's Disease

United States
Peking University Cancer Hospital & Institute

Recruiting

Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer (RESCUE-GC)

Gastric Cancer

China
Sun Yat-sen University

Unknown

Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer (CAPITAL)

Gastric Cancer

China
Zhejiang Cancer Hospital

Completed

S-1 and Radiotherapy in Elderly Patients With Esophageal Cancer

Esophageal Cancer

China
Taiho Oncology, Inc.
Quintiles, Inc.; United BioSource, LLC

Completed

Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer

Locally Advanced or Metastatic Pancreatic Cancer
TTY Biopharm
National Taiwan University Hospital; Chang Gung Memorial Hospital; Taipei Veterans... and other collaborators

Terminated

A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan

Pancreatic Cancer | Adjuvant Chemotherapy | Resected Pancreatic Cancer

Taiwan
Fudan University

Completed

S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Seoul National University Bundang Hospital

Unknown

S-1-induced Lacrimal Drainage Obstruction

Gastric Cancer

Korea, Republic of
Japan Clinical Cancer Research Organization
Kitasato University

Completed

Clinical Trial of Chemosensitivity Test

Gastric Cancer

Japan
Taiho Oncology, Inc.
Quintiles, Inc.; United BioSource, LLC

Completed

Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer
Hamamatsu University

Unknown

Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer

Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Colon Cancer

Japan
AstraZeneca

Recruiting

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (ARTEMIDE-Bil01)

Biliary Tract Cancer

France, Spain, United Kingdom, United States, Italy, Korea, Republic of, Belgium, Canada, Germany, Brazil, China, India, Japan, Taiwan, Australia, Thailand, Hong Kong, Denmark, Turkey, Poland, Norway
Anne Birgitte Raben
University of Leeds; Wageningen University; University of Liverpool; Maastricht... and other collaborators

Completed

Sweeteners and Sweetness Enhancers: Prolonged Effects on Health, Obesity and Safety (SWEET)

Obesity

Spain, Denmark, Netherlands, Greece
Taiho Pharmaceutical Co., Ltd.

Completed

Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)

Gastric Cancer

Japan
Shanghai Chest Hospital

Unknown

First-line Combination Treatment Based on Anlotinib

Lung Cancer | Advanced Stage

China
Lin Chen

Unknown

SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer (RESONANCE)

Gastric Adenocarcinoma

China
TTY Biopharm
National Taiwan University Hospital; Chang Gung Memorial Hospital; Taipei Veterans... and other collaborators

Completed

A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer(BTC)

Taiwan
Novacea
Schering-Plough

Suspended

A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

United States
Tragara Pharmaceuticals, Inc.

Completed

APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer

Pancreatic Cancer | Metastatic Pancreatic Cancer

United States
Hallym University Medical Center
Jeil Pharmaceutical Co., Ltd.

Completed

Gemcitabine and S-1 for Advanced Biliary Tract Cancer

Biliary Tract Neoplasm

Korea, Republic of
Taiho Oncology, Inc.

Completed

A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors

Tumors

United States
Centro Nacional de Investigaciones Oncologicas...
Apices Soluciones S.L.; Hospital Universitario de Fuenlabrada; Grupo Hospital...

Completed

Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets

Advanced Pancreatic Carcinoma

Spain
Peking Union Medical College Hospital

Recruiting

The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.

Efficacy and Safty of Camrelizumab Plus S-1 Maintenance After First-line Induction Chemotherapy for GC

China
AIO-Studien-gGmbH
Taiho Pharmaceutical Co., Ltd.; Nordic Pharma SAS

Completed

Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction (S-1 adjuvant)

Adenocarcinoma,Stomach | Adenocarcinoma, Esophagogastric Junction

Germany
Sun Yat-sen University

Unknown

Maintenance Treatment With S-1 in Gastric Cancer Patients

Gastric Cancer Stage IV | Cancer of Stomach

China
Fudan University

Terminated

SOX as Salvage Treatment in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Kyungpook National University Hospital

Unknown

S-1 Versus S-1 Plus Cisplatin as an Adjuvant Chemotherapy to Treat Gastric Cancer

Gastric Cancer

Korea, Republic of
Xinjiang Medical University

Unknown

Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation

Non-Small Cell Lung Cancer

China
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer (GEMCAD1003)

Pancreatic Adenocarcinoma

Spain
Albert Einstein College of Medicine
Shanghai Proton and Heavy Ion Center

Completed

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

Cancer | Pancreatic Cancer

United States, China
Chinese PLA General Hospital

Recruiting

RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

Advanced Gastroesophageal Adenocarcinoma

China
Zhejiang Provincial People's Hospital

Withdrawn

S-1 and Radiotherapy for Elderly Esophageal Cancer Patients

Esophageal Cancer | Radiotherapy | S-1

China

Search clinical trials for: GES (Gemcitabine, Erlotinib, S-1)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations